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Background: Dietary intake of n-3 polyunsaturated fatty acids (PUFA) is primarily recognized to protect against
cardiovascular diseases, cognitive dysfunctions and the onset of obesity and associated metabolic disorders.
However, some of their properties such as bioavailability can depend on their chemical carriers. The objective of
our study was to test the hypothesis that the nature of n-3 PUFA carrier results in different metabolic effects related
to adiposity, oxidative stress and inflammation.
Methods: 4 groups of C57BL/6 mice were fed for 8 weeks low fat (LF) diet or high-fat (HF, 20%) diets. Two groups
of high-fat diets were supplemented with long-chain n-3 PUFA either incorporated in the form of phospholipids
(HF-ω3PL) or triacylglycerols (HF-ω3TG).
Results: Both HF-ω3PL and HF-ω3TG diets reduced the plasma concentrations of (i) inflammatory markers such as
monocyte chemoattractant protein-1 (MCP-1) and interleukin 6 (IL-6), (ii) leptin and (iii) 4-hydroxy-2-nonenal (4-
HNE), a marker of n-6 PUFA-derived oxidative stress compared with the control HF diet. Moreover, in both HF-ω3PL
and HF-ω3TG groups, MCP-1 and IL-6 gene expressions were decreased in epididymal adipose tissue and the
mRNA level of gastrointestinal glutathione peroxidase GPx2, an antioxidant enzyme, was decreased in the jejunum
compared with the control HF diet. The type of n-3 PUFA carrier affected other outcomes. The phospholipid form
of n-3 PUFA increased the level of tocopherols in epididymal adipose tissue compared with HF-ω3TG and resulted
in smaller adipocytes than the two others HF groups. Adipocytes in the HF-ω3PL and LF groups were similar in size
distribution.
Conclusion: Supplementation of mice diet with long-chain n-3 PUFA during long-term consumption of high-fat
diets had the same lowering effects on inflammation regardless of triacyglycerol or phospholipid carrier, whereas
the location of these fatty acids on a PL carrier had a major effect on decreasing the size of adipocytes that was
not observed with the triacyglycerol carrier. Altogether, these results would support the development functional
foods containing LC n-3 PUFA in the form of PL in order to prevent some deleterious outcomes associated with
the development of obesity.
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Chronic inflammation and oxidative stress are recog-
nized as major factors involved in the pathogenesis of
several current metabolic diseases such as obesity, type 2
diabetes and cardiovascular diseases (CVD) [1-3].
Elevated levels of pro-inflammatory cytokines and
chemokines, such as interleukins (IL) and monocyte
chemotactic protein-1 (MCP-1), are hallmarks of the
metabolic syndrome [1,2]. It is now established that
white adipose tissue (WAT) is not only an energy-
storage tissue but also an endocrine organ that secretes
various bioactive molecules namely “adipokines” includ-
ing adiponectin, leptin, IL-6 and MCP-1, [4]. These
molecules have a key role in the regulation of systemic
and energy metabolism. Indeed, dysregulated production
of these adipokines due to WAT dysfunction and excess
adiposity can contribute to the pathogenesis of obesity
and insulin resistance [5]. High-fat intake has been re-
peatedly shown to play a significant part in the obesity-
associated low grade chronic inflammation, which is
characterized in human and mice by macrophage infil-
tration in WAT [6-9].
In this context, dietary supplementation with long-
chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), in
particular docosahexaenoic acid (DHA; 22:6 n-3) and ei-
cosapentaenoic acid (EPA; 20:5 n-3) presents a variety of
health benefits. These LC n-3 PUFA are known to be
protective by reducing inflammation in both blood and
WAT [6,10,11], improving lipid metabolism [12], decreas-
ing risk of CVD [13,14] and several neurodegerenative
diseases [15,16]. Therefore, nutritional recommendations
of 250 mg/day of EPA/DHA have been established in
Western societies for n-3 PUFA intake, to achieve nutrient
adequacy and lower n-6/n-3 PUFA ratio [17].
Dietary EPA and DHA are provided mostly by fatty
fish, where they are mainly esterified in triacylglycerols
(TG). In other sources such as krill, the major propor-
tion of these LC n-3 PUFA is esterified in phospholipids
(PL). Of note, compared with fish oil, krill oil contains
the same amount of DHA but a greater proportion of
EPA [18]. The latter is a major precursor of anti-
inflammatory eicosanoids [19]. Some authors have
compared the potential effects of different LC n-3 PUFA
formulations on lipid metabolism. The supplementation
of LC n-3 PUFA in the form of PL would exert superior
biological and nutritional functions compared to TG.
This would include (i) anti-inflammatory actions [20,21]
and antioxidant activities on the brain lipids [22], (ii)
improved memory and learning [23], (iii) reduced blood
and tissue lipids [24-26], (iv) increased bioavailability of
EPA and DHA in plasma [27,28] and (v) tendency to re-
duce obesity [21]. In humans, the effects of PL-bound
LC n-3 PUFA provided by krill oil on plasma lipids were
similar to those of TG-bound LC n-3 PUFA from fish oilbut at lower dose of LC n-3 PUFA [27]. In the rodent
studies, the amount of LC n-3 PUFA in the diets were
usually high, i.e. ~ 8–15% of total fats [21,26,29].
To date, available data are insufficient to assess
whether the supplementation of Western-type high-fat
(HF) diets with LC n-3 PUFA carried either by TG or by
PL can make any difference in the metabolic outcomes,
with an aim to prevent or treat metabolic disorders.
The aim of the present study was to test the hypoth-
esis that long-term intake of nutritional amounts of n-3
PUFA in realistic HF diets could exert different effects
according to the PL or TG carrier on (i) the develop-




OmegavieW Tuna oil 25 DHA flavorless was provided by
Polaris (Pleuven, France) as a source of triacylglycerol
rich in LC n-3 fatty acids. A lecithin rich in DHA was
enzymatically synthesized by Polaris (Pleuven, France)
and further purified by precipitation with cold acetone
to eliminate all traces of triacylglycerols and ethyl esters
[30]. As shown by HPLC paired with evaporative light-
scattering detector and external calibration curves, PL-
DHA was composed of lysophosphatidylcholine (lysoPC:
49.2 ± 0.7 wt%), phosphatidylcholine (PC; 33.5 ± 0.4 wt%),
phosphatidylinositol (PI; 9.0 ± 0.3 wt%), phosphatidy-
lethanolamine (PE: 4.8 ± 0.7 wt%) and sphingomyelin (3.5
± 0.2 wt%). Lard was supplied by Celys (Rezé, France) and
kiwi seed oil, as additional source of alpha-linolenic acid,
by Polaris (Pleuven, France). Sunflower oil (LesieurW) was
purchased from a local supermarket and oleic sunflower
oil from Olvéa (Marseille, France). The vegetable lecithin
rich in linoleic acid 18:2 n-6 (PL-LA) was sold by Lipoid
(Ludwigshafen, Germany) and was composed exclusively
of phosphatidylcholine and antioxidants (no TAG).
Preparation of lipid for mice diets
Low fat (LF), HF and the two HF lipid blends containing
LC n-3 PUFA in the form of PL or TG were prepared at
the labscale. DHA and, in lower amount, EPA were sup-
plied either in the form of triacylglycerols (HF-ω3TG) or
phospholipids (HF-ωPL). The fatty acid compositions of
both the tuna oil and the lecithin rich DHA product are
reported in Additional file 1. The four blends were
prepared by direct mixing of the different oils and fat
sources, including the lard in the proportions indicated
in Table 1. Then they were stored under a flux of nitro-
gen at −20°C and sent to SAFE (Augy, France) for pre-
paring the mice diets. The composition of the four diets
is reported Table 1. HF-ω3TG and HF-ω3PL are the
diets that served as unoxidized n-3 diet controls in our
other study about the impact of PUFA oxidation [30].
Table 1 Formulation of the experimental diets
High-fat containing n-3 PUFA as LF HF HF-ω3PL HF-ω3TG
Ingredient (g/100 g)
Lipid mixture 5 20 20 20
Among which:
Lard 2 18.10 18.10 18.06
Sunflower oil 0.64 1.1 0.6 0.2
Oleic sunflower 1.27 0.0 0.4 -
Kiwi seed oil 0.29 0.0 0.1 0.02
Tuna oil - - - 0.9
Phospholipids
PL-DHA - - 0.8 -
Lecithin PL-LA 0.8 0.8 - 0.8
Corn starch 54 39 39 39
Casein 20 20 20 20
Sucrose 10 10 10 10
Pure cellulose 5 5 5 5
Vitamin mixture 5 5 5 5
Mineral mixture 1 1 1 1
Tocopherolsa 0.000 0.084 0.099 0.092
Energy content (kJ/g) 14.88 18.14 18.14 18.14
Energy%
Protein 19.1 15.7 15.7 15.7
Carbohydrates 57.6 34.1 34.1 34.1
Lipids 12.8 41.5 41.5 41.5
aConsidering the difference observed in tocopherols in lipid mixtures, which
can affect their metabolic impact [31], care was taken to supplement lipid
mixtures with α-tocopherol during formulation to achieve iso-tocopherol diets.
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Male C57BL/6 mice (8 wk, 20 g) from Janvier SA (Le
Genest Saint-Isle, France) were housed in a temperature-
controlled room (22°C) with a 12 h light/12 h dark cycles.
After 2 weeks of chow diet, mice were randomly divided
into four groups fed one of the four following diets for 8 -
weeks: LF, HF, HF-ω3TG and HF-ω3PL diets. Animal
experiments were performed under the authorization
n°69-266-0501 (Direction Départementale des Services
Vétérinaires du Rhône, France). All experiments were
carried out in compliance with the French Ministry of
Agriculture guidelines (n° 87–848) and the E.U. Council
Directive for the Care and Use of Laboratory Animals of
November 24th, 1986 (86/609/EEC), in conformity with
the Public Health Service (PHS) Policy on Humane Care
and Use of Laboratory Animals. COS holds a special li-
cence (n° 69266257) to experiment on living vertebrates
issued by the French Ministry of Agriculture and Veterin-
ary Service Department. Body weight was measured twice
a week and food intake was measured weekly. After8 weeks, mice were euthanized by intraperitoneal (IP) in-
jection of sodium pentobarbital and blood was collected
by cardiac puncture under pyrogen-free conditions on
heparin-containing tubes. Plasma, liver, WAT, muscles,
duodenum and jejunum were collected. For analysis of
4-hydroxy-2-alkenals, due to plasma volume constraints, 3
pools of 300 μL obtained from 3 mice (100 μL per mice)
were used for each group.4-Hydroxy-2-alkenals: derivatization, analysis and
quantification
4-hydroxy-2-alkenals were derivatized from 300 μl of
plasma as described previously [32]. Deuterated 4-
hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal
(4-HHE) (20 ng) used as internal standards were
added to the samples. Briefly, they were treated with
O-2,3,4,5,6-pentafluorobenzyl hydroxylamine hydro-
chloride. After acidification with H2SO4, pentafluo-
robenzyloxime derivatives were extracted with methanol
and hexane. The hydroxyl group was then converted into
trimethylsilylether after an overnight treatment with N,O-
bis(trimethylsilyl)trifluoroacetamide at room temperature.
The pentafluorobenzyloxime trimethylsilylether derivatives
of 4-HHE (O-PFB-TMS-4-HHE) and 4-HNE (O-PFB-
TMS-4-HNE) were then analyzed by GC-MS using nega-
tive ion chemical ionization (NICI) mode on a Hewlett-
Packard quadripole mass spectrometer interfaced [32] with
a Hewlett-Packard gas chromatograph (Les Ullis, France).
For the determination of 4-hydroxy-2-alkenals in liver, the
tissue was firstly minced in liquid nitrogen with PIPES,
then centrifuged and the supernatant treated as previously
described. Regarding WAT, a protocol has been adapted to
the extraction and derivatization of 4-hydroxy-2-alkenals
in lipophilic media. Briefly the o-pentafluorobenzyl
hydroxylamine was prepared by dilution in hexane
containing pure triethylamine leading to the formation of a
precipitate, which was removed. Oxime derivatives were
then prepared and extracted with hexane. Lipids were re-
move by solid phase extraction on silica cartridge, and the
oxime derivatives were eluated with hexane/diethyl ether
(50/50, vol/vol). The second derivatization (silylation) was
achieved as previously described. The method allowed the
quantification of free 4-HHE and 4-HNE.sCD14, LBP, IL-6, MCP-1, leptin, adiponectin, insulin and
glucose measurements
MCP-1, IL-6 (Clinisciences, France), sCD14, LBP (Enzo
Life Sciences), leptin, adiponectin (SpiBio, Montigny Le
Bretonneux, France) and insulin (Crystal Chem Inc.,
USA) plasma levels were assayed by ELISA kits according
to the manufacturer’s instructions. Blood glucose levels
were measured on animals in mouse-tail blood using a
glucometer (Accu-Chek W, Roche, France).
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Plasma triacyglycerols (TAG) were measured with the tri-
glyceride PAP kit (BioMérieux France) as previously
described [33]. Plasma TAG concentration was calculated
by subtracting the free glycerol in plasma measured
with the glycerol UV-method (R-Biopharm/Boehringer,
Mannheim, Germany). Plasma NEFA was measured
using NEFA-C kit (Wako Chemicals, Neuss, Germany).
Fatty acid analysis
Total lipids were extracted from 35 μL of plasma as
described previously [33] and from tissues according to
Folch et al. [34]. The organic phase (solvent) was
evaporated under N2 and total fatty acids were
transesterified using boron trifluoride in methanol (BF3/
methanol) and in the presence of heptadecanoic acid
(C17:0, Sigma, France) as an internal standard [33]. The
FA methyl esters were then analyzed by GC using a
DELSI instrument model DI 200 equipped with a fused
silica capillary SP-2380 column (60 m × 0.22 mm).
Quantification of tocopherols
Tocopherols in epipidymal WAT (eWAT) and retroperi-
toneal WAT (rWAT) were quantified without saponifi-
cation according to a method described by [35]. An
aliquot of lipid extract was dried under N2, then
solubilized in n-hexane and analyzed by HPLC paired
with a fluorimeter detector (λex = 295 nm and λem =
330 nm). Separation of the different isomers of
tocopherols and tocotrienols was achieved on a polar
column (Acclaim Polar advantage II, Dionex, 3 μm; 250
× 3 mm) in isocratic mode at 0.5 ml/min with hexane/
methyl-terbutyl-ether 90/10, vol/vol. The quantification
was realized by comparison of the peak areas with cali-
bration curves performed with external standard
solutions of α, γ, β and δ tocopherols (Calbiochem, toc-
opherol set) and γ tocotrienol (Sigma, France). An ali-
quot of each diet was saponified for 30 min at 70°C in a
mixture containing potassium hydroxide (50% w/vol in
water), pyrogallol in ethanol (1% w/vol). Tocopherols
were extracted with hexane containing 0.005% (w/vol) of
BHT. After centrifugation and washing, the organic
phase was mixed. The solvent was removed under vac-
uum, and then under a stream of nitrogen. Tocopherols
were finally dissolved in n-hexane and then quantified as
described previously.
Cellularity study: measurement of adipocyte size and
number
Preparation of adipose tissue for determination of cell
size was performed essentially as described previously
[36]. Briefly, 30–40 mg of eWAT or rWAT was
immediately fixed in osmium tetroxide for 96 hours at
room temperature. After washing, adipose cell-sizedistribution was then assessed using a Beckman Coulter
Multisizer IV (Beckman Coulter) with a 400 μm aper-
ture. The range of cell-sizes that can effectively be
measured using this aperture is 20–240 μm. The instru-
ment was set to count 1000 particles per run, and the
fixed-cell suspension was diluted so that coincident
counting was less than 10%. After collection of pulse
sizes, the data were expressed as particle diameters and
displayed as histograms of counts against diameter using
linear bins and a linear scale for the cell diameter. Cell-
size distributions were drawn from measurement of at
least 12 000 cell diameters per animal. Mean cell weight
was calculated as measured Cell volume × TG density
(0.9); cell number were calculated as Cell weight/WAT
mass (eWAT or rWAT).
Quantitative PCR analysis
Total RNA was extracted from 50 mg of duodenum and
jejunum of mice using the NucleoSpinW RNA/Protein
kit (Macherey Nagel, Duren, Germany), and from 50 mg
of eWAT or rWAT with TRIzol (Invitrogen, Eragny,
France). cDNAs were synthesized from 1 μg of total
RNA in the presence of 100 units of Superscript II
(Invitrogen, France) with a mixture of random hexamers
and oligo (dt) primers (Promega, Charbonnières, France).
The amount of target mRNAs was measured by RT,
followed by real-time PCR, using a Rotor-Gene Q
(Qiagen, France). The amount of target mRNAs was
measured by RT, followed by real-time PCR, using a
Rotor-Gene Q (Qiagen, France). Primer sequence and
RT-quantitative PCR conditions are available upon
request (cyrille.debard@univ-lyon1.fr). Hypoxanthine guan-
ine phosphoribosyl transferase (HPRT) mRNA was used to
normalize data of duodenum, jejunum and WAT of mice.
Statistical analysis
All data are presented as means ± SEM and were
analysed using Statview 5.0 software (Abacus Concept,
Berkeley). One-way ANOVA followed by Fisher PLSD
was used to compare the four groups. Differences were
considered significant at P < 0.05.
Results
Diet compositions
Table 2 shows that we succeeded in producing diets
equilibrated in terms of n-3 PUFA supplies and n-6/n-3
ratios, with LC n-3 PUFA in the form of PL or TG. Im-
portantly, HF-ω3TG diet, HF diet and LF diet also
contained PL in the form of PL-LA lecithin, so that
effects of PL-ω3 can be attributed to the molecular form
of LC n-3 PUFA in the diet, not to the presence of
phospholipids.
The HF-ω3PL diet contained slightly less n-3 PUFA
than the HF-ω3TG diet, as frequently found in dietary n-3
Table 2 Fatty acid composition in the diets
FA mg/g diet LF HF HF-ω3PL HF-ω3TG
SFA 11.3 ± 1.6 71 ± 12$ 64 ± 1$ 66 ± 5$
MUFA 24 ± 6 82 ± 14$ 76 ± 1$ 72 ± 5$
n-6 PUFA 12 ± 2 29 ± 5$ 21 ± 1$ 21 ± 1$
n-3 PUFA 2.1 ± 0.2 2.0 ± 0.4 2.8 ± 0.2$* 3.9 ± 0.1$*
Among which 18 :3 n-3 2.1 ± 0.2 2.0 ± 0.4 2.0 ± 0.1 1.9 ± 0.1
20 :5 n-3 - - 0.2 ± 0.0$*£ 0.4 ± 0.2$*
22 :6 n-3 - - 2.8 ± 0.2$*£ 3.9 ± 0.2$*
Total PUFA 13.8 ± 2.3 30.4 ± 5$ 23.7 ± 0.4$ 25.0 ± 1.4$
n-6/n-3 ratio 5.4 ± 0.4* 14.3 ± 0.3 7.7 ± 0.5* 5.4 ± 0.2*
Total FA 49 ± 9 184 ± 31$ 163 ± 2$ 162 ±11$
α-tocopherol (μg/g chow) 185 ± 6 219 ± 4 201 ± 1 207 ± 18
(*P < 0.05 vs HF); ($P < 0.05 vs LF), (£P < 0.05 vs HF-w3TG). ANOVA followed by
Fisher test. Data are mean ± SEM for n = 3. Abbreviations: FA, fatty acids;
MUFA, monounsaturated fatty acids; SFA, saturated fatty acids.
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contents and n-6/n-3 ratios were consistent with dietary
recommendations, whereas n-6/n-3 ratio was nearly 15 in
HF diet as observed in human Western diets.
PL-ω3 and TG-ω3 in high-fat diet modify biometric
parameters
As shown in Table 3, the supplementation of HF diets
with LC n-3 PUFA decreased the body weight gain in




Initial Body weight (g) 24.1 ± 0.4
Body weight gain (g) 4.1 ± 0.1
Energy Intake (kJ/mouse/d) 39.1 ± 0.9
Liver weight (g) 1.39 ± 0.03
WAT weight (g) 0.84 ± 0.05
Gastrocnemius (g) 0.16 ± 0.0
Plasma lipids
TAG (mM) 0.89 ± 0.06
NEFA (mM) 0.62 ± 0.5
Glucose (mmol/L) 9.1 ± 0.8
Plasma insulin (pmol/L) 37.0 ± 6.9
Liver lipids (mg total fatty acids/g tissue) 30.3 ± 2.9
Lipid peroxidation markers in plasma (nM)
4-HHE 23.3 ± 13.5
4-HNE 4.9 ± 0.3*
(*P < 0.05 vs HF); ($P < 0.05 vs LF), ANOVA followed by Fisher test.
Data are mean ± SEM for n = 8 per group. Abbreviations: WAT, white adipose tissue
-2-hexenal; 4-HNE, 4-hydroxy-2-nonenal.
For 4-hydroxy-2-alkenals analysis, 3 pools of 300 μL obtained from 3 mice (100 μL pω3TG mice. Liver weight was significantly lower in mice
fed HF-ω3PL or HF-ω3TG diets compared to HF group,
and even lower than LF group regarding HF-ω3PL.
White adipose tissue weight (total of retroperitoneal,
epididymal and subcutaneous adipose tissues) was also
lower in HF-ω3PL group than in HF group but no sig-
nificant difference was observed between HF-ω3PL and
HF-ω3TG groups. However, the lean mass estimated by
the weight of gastrocnemius muscle was not different be-
tween the groups (Table 3).
Energy intake was evaluated during the 8 weeks of
feeding trial. Table 3 shows that it was higher in the
three HF groups than in LF group. However, results did
not show any difference between HF-ω3PL and HF-
ω3TG groups. After 8 weeks feeding, free fatty acid and
triacyglycerol concentrations were lower (P < 0.05) in the
plasma of the three groups of mice fed HF diets, regard-
less of supplementation with n-3 PUFA, than in LF
group (Table 3). Plasma insulin and glucose levels did
not differ among the groups. Neither plasma free fatty
acid nor triacyglycerol concentrations were significantly
different between the three groups of mice fed HF diets.
Hepatic lipid accumulation was similar among groups.
Fatty acid composition in plasma and tissues reflects the
enrichment with PL-ω3 and TG-ω3 in the high-fat diets
Fatty acid composition of total plasma, liver and WAT
were characterized to investigate whether long-termid concentrations of mice
Mice groups according to dietary lipids
HF HF-ω3PL HF-ω3TG
24.2 ± 0.3 23.9 ± 0.3 24.5 ± 0.3
4.2 ± 0.5 3.1 ± 0.1*$ 3.7 ± 0.3
68.9 ± 0.3$ 60.2 ± 1.3$ 59.8 ± 1.3$
1.36 ± 0.03 1.21 ± 0.04*$ 1.27 ± 0.04*
1.03 ± 0.12 0.72 ± 0.05* 0.93 ± 0.11
0.16 ± 0.0 0.16 ± 0.0 0.15 ± 0.0
0.66 ± 0.09$ 0.64 ± 0.04$ 0.57 ± 0.04$
0.35 ± 0.02$ 0.27 ± 0.01$ 0.37 ± 0.02$
8.6 ± 0.5 9.4 ± 0.9 9.2 ± 0.7
36.8 ± 3.0 24.5 ± 3.0 26.5 ± 4.8
34.0 ± 3.0 30.3 ± 0.6 33.1 ± 3.7
103.7 ± 36.5 88.8 ± 32.0 128.0 ± 37.5
13.4 ± 0.5 5.9 ± 1.1* 8.6 ± 0.3*
; TAG, plasma triacyglycerols; NEFA, non-esterified fatty acids; 4-HHE, 4-hydroxy
er mice) were used for each group (n = 3).
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tabolism. In fact, the profile of total FA in plasma
(Table 4), in liver and eWAT (See Additional file 2)
reflected the composition of ingested dietary fats
(Table 2). FA profile of rWAT was similar to that of
eWAT (See Additional file 3).
Table 4 shows that the plasma arachidonic acid (20:4
n-6), an n-6 FA precursor of pro-inflammatory
mediators in biological membranes, was significantly
higher in HF group than in three other groups. EPA pro-
portion was higher in plasma of mice fed the HF diets
supplemented with n-3 PUFA compared with HF group,
and higher in HF-ω3TG group than in HF-ω3PL group.
Importantly, plasma DHA was higher in the two HF
groups supplemented with LC n-3 PUFA in the form of
PL or TG compared with LF and HF groups. Addition-
ally, the proportions of LC n-3 PUFA (EPA and DHA)
were higher in the HF-ω3TG group than in the HF-
ω3PL group as observed in the diets.
In liver like in eWAT, DHA and EPA levels were sig-
nificantly increased in both HF-ω3PL and HF-ω3TG
groups compared to LF and HF groups. A significant dif-
ference of LC n-3 PUFA levels was observed between
HF-ω3PL and HF-ω3TG groups (See Additional file 2),
as observed in the plasma. The n-6/n-3 ratio, related to
a risk of inflammation derived from PUFA metabolites,
was higher in mice fed HF diet than the three other
groups. This ratio was not different between HF-ω3PL
and HF-ω3TG groups (Table 4 and Additional file 2).
The relative difference of n-6/n-3 ratio that existed be-
tween the high-fat diets and the LF diet was altogether
still observed in plasma and tissues after 8 weeks of dietTable 4 Fatty acid profile in plasma in mice fed different diet
Major FA in plasma LF
Total FA (mol/100 mol FA):
SFA 33.7 ± 0.3
16:1 n-7 4.0 ± 0.5
18:1 n-7 2.7 ± 0.2
18:1 n-9 19.3 ± 1.9
MUFA 27.9 ± 1.0
18:2 n-6 21.2 ± 0.6
20:4 n-6 9.6 ± 1.2*
n-6 33.1 ± 0.9*
18:3 n-3 0.4 ± 0.1
20:5 n-3 0.7 ± 0.0
22:6 n-3 3.8 ± 0.4
n-3 5.2 ± 0.4
n-6/n-3 ratio 6.4 ± 0.3*
(*P < 0.05 vs HF), ($P < 0.05 vs LF), (£P < 0.05 vs HF-ω3TG). Data are mean ± SEM for n
monounsaturated fatty acids; SFA, saturated fatty acids.(Figure 1). Altogether, both diets enriched in LC n-3
PUFA resulted in proper accretion of these FA in tissues.
Effects of PL-ω3 and TG-ω3 in high-fat diet on plasma
markers of inflammation, metabolic endotoxemia and
oxidative stress
High-fat diets are known to induce a metabolic inflam-
mation related to (i) the concentrations of different types
of adipokines and (ii) endotoxin transport. Regarding in-
flammation, we show higher concentrations in plasma of
the chemokine MCP-1 (Figure 2A) in HF group than in
the three other groups. Plasma interleukin IL-6 was also
significantly higher in HF group than in HF-ω3PL group
(Figure 2B) and tended to be higher in HF group than in
HF-ω3TG mice (P = 0.06). Both n-3 diets even resulted
in plasma concentrations of inflammatory markers simi-
lar to the LF diet. Among plasma markers involved in
the transport of the pro-inflammatory endotoxins, the
lipopolysaccharide binding protein (LBP) level was
higher in plasma of HF mice than in LF and HF-ω3PL
groups (Figure 2C). However, no difference was found
between HF and HF-ω3TG groups or between HF-ω3PL
and HF-ω3TG groups. The plasma level of soluble clus-
ter of differentiation 14 (sCD14), an endotoxin receptor,
was also higher in HF mice than in the two HF groups
supplemented with LC n-3 PUFA (Figure 2D). Regarding
adipokines in plasma, results showed an increased leptin
concentration in the HF group vs all other groups
(Figure 2E). Supplementation with LC n-3 PUFA in both
forms allowed recovering leptin concentrations similar
to LF group. In contrast, there was no difference in plasma
adiponectin concentration among the groups (Figure 2F).s
HF HF-ω3PL HF-ω3TG
34.5 ± 0.2 34.4 ± 1.3 36.1 ± 2.6
1.6 ± 0.2$ 1.2 ± 0.02$ 1.6 ± 0.4$
1.5 ± 0.1$ 1.3 ± 0.1$ 1.4 ± 0.3$
15.6 ± 0.7$ 16.1 ± 1.9$ 13.4 ± 6.7$
19.6 ± 0.3$ 19.5 ± 0.2$ 17.3 ± 6.7$
25.4 ± 0.2$ 26.1 ± 0.4$ 26.4 ± 0.8$
14.3 ± 0.4 11.2 ± 0.5* 9.5 ± 0.8*
42.1 ± 0.5 39.2 ± 1.0$ 38.2 ± 3.2$*
Tr$ 0.3 ± 0.0*$ 0.2 ± 0.0$*
Tr$ 0.7 ± 0.0*£ 1.2 ± 0.1$*
3.2 ± 0.1 4.9 ± 0.3$*£ 6.6 ± 0.5$*
3.9 ± 0.1$ 6.4 ± 0.2*£ 8.4 ± 1.3$*
10.9 ± 0.4 6.1 ± 0.2* 4.6 ± 0.4*













































Figure 1 Relative n-6/n-3 fatty acid ratio in diets, plasma, Liver
and WAT. The mice were fed LF, HF, HF-ω3PL and HF-ω3TG diets.
The values were expressed as percentage of the ratio measured in
the groups. Data are means ± SEM (n = 3-6).
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http://www.nutritionandmetabolism.com/content/10/1/23LC PUFA are known to be prone to oxidation because
of their high degree of unsaturation. They form oxidized
end-products which contribute to oxidative stress. We
measured the levels of 4-hydroxy-2-hexenal (4-HHE)
and 4-hydroxy-2-nonenal (4-HNE), two markers of lipid
peroxidation derived from the oxidation of n-3 PUFA
and n-6 PUFA respectively. As shown in Table 3, the
plasma level of 4-HHE did not differ among the groups,
although there was large variation within groups. The
plasma level of 4-HNE was significantly higher in HF
group than in the three other groups albeit remaining
low (Table 3). No differences in 4-HHE and 4-HNE
concentrations were observed in the liver that is a major
target organ for these alkenals (0.5 to 2 nmol/g regard-
less of group).
PL-ω3 and TG-ω3 in high-fat diet improve markers
related to inflammation and oxidative stress in WAT
Because we noticed a significant decrease of inflamma-
tory markers in the plasma of mice fed HF diet
supplemented with LC n-3 PUFA, we examined the
MCP-1 and IL-6 gene expression in WAT. MCP-1 ex-
pression in eWAT was significantly higher in HF group
than in the other groups (Figure 3A, P < 0.01). The same
difference between HF and HF-ω3PL groups was
observed in rWAT (see Additional file 4). The expres-
sion of mRNA IL-6 was significantly decreased in HF-
ω3TG group compared to HF group and tended to be
decreased in HF-ω3PL group compared to HF group
(Figure 3B). In addition, the level of tocopherols was
higher in eWAT of mice fed HF-ω3PL and HF-ω3TG
diets than LF and HF groups (Figure 3C). Noticeably,
the level of tocopherols was higher in HF-ω3PL group
than in HF-ω3TG group (P < 0.05) despite the similar
levels found in the diets (Table 2). The concentration ofthe oxidation products 4-HHE and 4-HNE in eWAT and
rWAT was similar among groups, in the range 0.5 to
2 nmol per g.
PL-ω3 and TG-ω3 in high-fat diet affect adipocyte size
distribution in WAT differently
To know whether the high-fat diets could affect the size
and the number of adipocytes in mice, we performed a
cellularity analysis of WAT. As shown Figure 4, the size
distribution of the epididymal adipocytes in the HF-
ω3PL group showed a marked shift toward smaller sizes
compared with HF and HF-ω3TG groups. The same ef-
fect was observed in retroperitoneal fat pads. The cellu-
lar characteristics of eWAT in mice fed HF and HF
supplemented with LC n-3 PUFA in the form of PL or
TG are shown in Table 5. A reduction of fat accretion in
eWAT was observed in HF-ω3PL group vs HF group
but no difference was observed between HF-ω3TG and
the two other groups. Adipocyte sizes in HF-ω3PL and
LF groups were actually similar. This reduction resulted
from a decrease in adipose cell volume rather than from
a decrease in the total number of adipocytes per fat pad,
as calculated from the measured size distribution.
Indeed, mean adipocyte diameter was reduced by 14%
in HF-ω3PL group vs HF group (P < 0.05) resulting
in a 30% decrease in calculated adipose cell volume
(P = 0.03).
Effect of PL-ω3 and TG-ω3 in high-fat diet on oxidative
stress in the small intestine
The upper small intestine represents the primary defense
line of the organism that can affect metabolism and in-
flammation. We thus examined the gene expression of
gastrointestinal glutathione peroxidase 2 (GPx2), mainly
expressed in the small intestine and implicated in the
detoxification of lipid oxidation products including
4-HHE and 4-HNE. The expression of GPx2 in the duo-
denum was higher in HF mice than in LF and HF-ω3PL
groups (Figure 5A). In the jejunum, the gene expression
of GPx2 was significantly increased in HF group
compared with the three other groups (Figure 5B).
Discussion
In the present study, we investigated (i) the effects of
long-term consumption of HF diet supplemented with
LC n-3 PUFA in the form of PL or TG on adiposity, oxi-
dative stress and inflammation and (ii) whether the PL
or TG carrier can affect these parameters. For this pur-
pose, we designed a HF diet containing 20% of fat, rich
in saturated fatty acids and with a relatively high n-6/n-3
ratio to mimic the lipid-enriched foods as consumed in
typical Western diets. Importantly, all diets contained
the same amount of PL, in the form of PL-DHA in HF-




















































































































































































Figure 2 Inflammation and endotoxin metabolism parameters in plasma of mice fed different diets. (A) monocyte chemoattractant
protein-1 (MCP-1; pg/ml); (B) Interleukin-6 (IL-6; μg/ml). (C) lipopolysaccharide binding protein (LBP; μg/ml). (D) (soluble cluster of differentiation
14 (sCD14; μg/ml). (E) leptin (ng/ml); (F) Adiponectin (μg/ml). Data are means ± SEM (n = 6-8). (*P < 0.05 vs HF); ($P < 0.05 vs LF). ANOVA followed
by Fisher test.
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http://www.nutritionandmetabolism.com/content/10/1/23groups. This formulation ensured that the possible
observed effects of PL-ω3 can be attributed to the loca-
tion of n-3 PUFA in the diet (on PL rather than TG) and
not to the presence of polar lipids that would have
biased the interpretation.
We show that altogether, long-term intake of HF diet
supplemented with LC n-3 PUFA protects against in-
flammation and oxidative stress induced by HF diets.
This is in agreement with numerous studies documenting
the beneficial health effects of LC n-3 PUFA [19,37]. Inthis study, the supplementation of HF diet with LC n-3
PUFA in the PL carrier was slightly lower than that in the
TG carrier. Therefore, our results indicate that the effects
of LC n-3 PUFA from lecithin rich in PL-DHA is more
efficient than LC n-3 PUFA from tuna oil (mainly TG-
DHA). This supports the results of a previous study
reporting that in healthy humans the metabolic effects of
krill oil (mainly PL) are similar to those of fish oil but at
lower dose of LC n-3 PUFA [27]. Importantly in previous




























































































Figure 3 Inflammatory markers and tocopherol level in
epididymal white adipose tissue (eWAT). MCP1 mRNA (A); IL-6
mRNA (B) and Tocopherol (μg/g lipids) (C). RT-quantitative PCR
results of mRNA expression. Tocopherol level was measured as
described in Materials & Methods. Bars represents means ± SEM of n
= 5-6 mice. (*P < 0.05 vs HF); ($P < 0.05 vs LF); (£P < 0.05 vs HF-ω3TG).
ANOVA followed by Fisher test.
Figure 4 Frequency evolution of adipocyte size of mice in
epididymal fat pad. Individual measurements were performed on
12 000–14 000 adipocytes using osmium tetroxide - coulter counter
procedure as described in Methods. Note that distribution of
adipocyte size was shifted leftward (ie. Towards smaller size) in HF-
ω3PL mice compared to HF and HF-ω3TG mice. Value are shown for
one representative curve for each group.
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http://www.nutritionandmetabolism.com/content/10/1/23sources, i.e. krill oil [25-28]. Usually, the percentage of PL
in these products is 40%, which means that a part of n-3
PUFA brought by the krill oil was in fact bound to TG
carrier in these studies.
In the present study, a dietary intake of LC n-3 PUFA
during 8 weeks resulted in an increased incorporation of
DHA into plasma, liver and WAT lipids, the FA com-
position of the organs reflecting the fatty acid profiles of
the diets. Regardless of the LC n-3 PUFA carrier, the
n-6/n-3 ratio in plasma, liver and WAT of mice fed HF-
ω3PL and HF- ω3TG was lower than in the HF diet.
The ratio was almost similar in both HF-ω3PL and HF-
ω3TG groups, while the HF-ω3TG group showed a sig-
nificantly higher proportion of DHA than the HF-ω3PL
group. A decreased n-6/n-3 ratio in tissues has been
reported to reduce atherosclerosis due to the inhibition
of systemic and vascular inflammation in apolipoprotein
E-deficient mice. The authors attributed these protective
effects to the anti-inflammatory properties of n-3 PUFA
[38]. In addition, the proportion of EPA in WAT was
higher in mice fed the HF diets supplemented with LC
n-3 PUFA compared with HF, suggesting that the turn-
over of DHA in eWAT is high. The increase in EPA
concentration paralleled the increased level of DHA in
HF-ω3TG more than in HF-ω3PL.
LC n-3 PUFA are known to reduce metabolic inflam-
mation in human and rodents [39-41]. Our data show
that the HF diet induced higher IL-6, MCP-1 levels in
plasma and in eWAT than LF diet. Interestingly, no acti-
vation of these pro-inflammatory markers was observed
in HF-ω3PL and in HF-ω3TG groups, even if the EPA +
DHA dose in the HF- ω3PL is lower of that in the HF-
ω3TG group. This may indicate that LC n-3 PUFA
derived from PL provide a better bioavailability and/or
bioactivity than those esterified into TG. Our results
Table 5 Comparison of adipose cell size variables in eWAT of LF, HF, HF-ω3PL and HF-ω3TG mice
LF HF HF-ω3PL HF-ω3TG
eWAT
eWAT (mg) 502 ± 29 588 ± 69 423 ± 21* 536 ± 59
Mode (μm) 77.3 ± 3.9* 89.3 ± 6.0 75.6 ± 1.8*£ 84.9 ± 5.5
Cell diameter (μm) 67.1 ± 3.1# 74.6 ± 3.4 64.3 ± 3.0* 70.5 ± 4.1
Cell weight (ng) 455.5 ± 46.5# 619.9 ± 49.2 434.8 ± 42.9* 496.5 ± 99.8
Nb cells (x106) 1.19 ± 0.01 1.12 ± 0.14 1.03 ± 0.07 0.99 ± 0.07
(*P < 0.05 vs HF); (#P = 0.07 vs HF); (£P < 0.05 vs HF-ω3TG).
Data are mean ± SEM for n = 4-5 per group. Abbreviations: eWAT, epididymal white adipose tissue.
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form, could inhibit the low-grade inflammation by dir-
ectly inhibiting macrophage immigration through the in-
hibition of MCP-1.
Our data are consistent with previous studies
reporting that the inflammatory response in WAT
induced by HF diet in obese diabetic animals was
prevented by the supplementation HF with n-3 PUFA ei-
ther in the form of PL or TG [6,21]. Batetta et al.
concluded that such anti-inflammatory effects can be
due to observed lower levels of arachidonic acid in
membrane phospholipids [24].
Recent studies revealed the complementary role of
metabolic endoxotemia in the low-grade inflammation.
Laugerette et al. observed that endotoxin transporter
LBP was positively correlated with plasma IL-6 in mice
fed a palm oil-based high-fat diet, which was reversed
using rapeseed oil [42]. Other works evidenced a link be-
tween low-grade inflammation or related metabolic
disorders and plasma LBP and sCD14 [43,44]. In our
study, the HF group presented the highest plasma con-
centration of LBP, consistently with inflammatory
markers. A significant decrease in the level of plasma
sCD14 was observed in HF-ω3PL and HF-ω3TG groups.































Figure 5 Expression of gastro-intestinal glutathione peroxidase 2 (GP
mice fed LF, HF, HF-ω3PL and HF-ω3TG diets during 8 weeks. This analysis
(*P < 0.05 vs HF); ANOVA followed by Fisher test.of HF diet with LC n-3 PUFA can lower plasma
concentrations of endotoxin transporters. Further
mechanisms should be investigated to elucidate the im-
plication of n-3 PUFA sources in the regulation of
endotoxemia-induced metabolic inflammation.
Circulating leptin levels are directly associated with
the mass of WAT and inflammation [45]. Our results
showed that the plasma levels of leptin, mainly produced
by adipocytes, were decreased in the two supplemented
groups with LC n-3 PUFA in the form of PL or TG vs
HF mice. Plasma leptin was also lower in HF-ω3TG
group independently of WAT mass, suggesting a rela-
tionship between the lower metabolic inflammation and
the leptin. Our results are in agreement with a previous
study showing that long-term intake of dietary n-3
PUFA by rats resulted in a significant decrease in plasma
leptin levels [46].
Adiponectin plays an important role as insulin-
sensitizing adipokine which production is decreased in
obesity and in conditions associated with insulin resist-
ance [5,47]. In our study, we did not observed a signifi-
cant difference in circulating adiponectin level among
groups. In addition, the glucose and insulin tolerances
were not affected by the different diets. Our results are





























x2) RNA in the small intestine. (A) duodenum and (B) jejunum of
was quantified by qPCR. Bars represents means ± SEM of n = 5-6 mice.
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http://www.nutritionandmetabolism.com/content/10/1/23of adiponectin was not different between HF group (35%
of fat) and DHA/EPA in the form of PL or TG
supplemented to the HF diets for 8 weeks [21]. Con-
versely, other studies showed a decrease in the level of
plasma adiponectin after feeding mice a HF diet; this
level was restored by the supplementation HF diet with
DHA and EPA [6,29]. Altogether, such modifications in
plasma adiponectin concentrations are reported with dif-
ferent lipid types (n-6 PUFA-rich corn oil instead of
lard) and/or concentrations in the diet (35% w/w instead
of 20%) and using larger doses of fish oil (15-40% in
total dietary lipids) compared with the present study
(5%).
Regarding adiposity, HF diet did not induce signifi-
cantly higher body weight gain than the low fat control,
although a trend towards heavier adipose tissue was
observed. This can be due to our choice of preparing LF
and HF groups using similar ingredients. Both LF and
HF were semi-synthetic and based mainly on corn starch
and casein, while many studies in the literature reach
weight gain by comparing semi-synthetic high-fat diet
with regular chow based on more various ingredients
[48]. Among the HF diets, HF-ω3PL diet led to a lower
weight gain and a reduced adipose tissue compared with
HF group without affecting the mass of muscles. How-
ever these effects were not observed in mice fed HF-
ω3TG. These results suggest that the PL carrier can
decrease body fat deposition more than the TG carrier.
This is consistent with a previous study reporting that
obese mice fed LC n-3 PUFA carried by PL developed
less body weight gain than those fed LC n-3 PUFA
carried by TG [21]. We further investigated the effect of
HF diet containing LC n-3 PUFA in the form of PL or
TG on the cell size distribution of adipose tissue by
using the Coulter counter method (Multisizer IV,
Beckman Coulter) which allows a more precise cell-size
distribution because the number of cell counted is much
higher than the one of microscopic methods. The most
noticeable difference between groups was in the adipo-
cyte size distribution. Mice fed HF diet showed an
increased adipocyte size compared with those fed the LF
diet. Differential effects were observed regarding LC n-3
PUFA supplementation; HF-ω3PL and LF diets induced
similar adipocyte size whereas HF-ω3TG and HF diets
led to larger adipocytes. Our results following a 20% w/
w high-fat diet for 8 weeks are consistent with those of
Rossmeisl et al. [21]. These authors observed that the PL
carrier decreased adipocyte area compared with the con-
trol HF diet in obese mice, which was not observed
using the TG carrier. Of note, endothelial lipase presents
specificity towards DHA-containing PL, thus generating
Lyso-PL containing DHA [49]. Moreover, our PL source
also contained Lyso-PC-DHA. We may hypothesize that
such DHA-containing lipid species might exert specificbiological activity, because superior biological effects of
LysoPC-DHA have otherwise been demonstrated regarding
DHA accretion in the brain and anti-inflammatory activity
[50,51]. However, further research is required to better
understand the mechanism of action of PL carrier.
Skurk et al. investigated the secretory capacity of adi-
pocyte fractions from the same individual. They
demonstrated that the large adipocytes were implicated
in the induction of pro-inflammatory genes such as
those coding for IL-6 and MCP-1 [52]. Consistently, HF
diet-induced-inflammation can be associated with large
adipocytes. Regarding the impact of supplementing with
n-3 PUFA, noticeably, the HF-ω3PL diet had a greater
anti-adiposity effect than the HF-ω3TG diet associated
with smaller adipocytes. Here, the anti-adiposity effect of
HF-ω3PL diet could be partly associated with the lower
metabolic inflammation in the mice. In contrast, the
anti-inflammatory effect of HF-ω3TG was not associated
with a decrease in adiposity.
We further investigated the effect of the composition
of the dietary high-fat, and more specifically of the pres-
ence of LC n-3 PUFA on lipid peroxidation and oxida-
tive stress. LC PUFA are molecules susceptible to
oxidation because they contain many double bonds.
PUFA oxidation leads to the formation of secondary
end-products such as 4-HNE derived from n-6 PUFA
and 4-HHE derived from n-3 PUFA [53]. Our previous
studies in mice showed that these markers can induce
oxidative stress and inflammation, even when consumed
in moderately oxidized dietary fat [30]. They also pro-
voke oxidative stress in vitro in Caco-2 cells [30]. In the
present study, similar levels of plasma 4-HHE were
measured in the three HF mice groups; however the
plasma level of 4-HNE was increased in HF mice
compared with the other groups. Previously, Esterbauer
et al. found that the basal concentrations of 4-HNE in
the human serum were in the range 0–700 nM. In our
study, plasma 4-HNE in mice remained within this range
observed in humans [54]. In liver and in WAT, the levels
of 4-hydroxy-2-alkenals were lower than 2 nmol/g,
which is in the same order of magnitude than in another
study reporting basal concentrations of 4-HNE in the
liver of mice [55]. We thus suggest that the dietary high-
fat used in this study may slightly enhance the oxidative
stress through the induction of 4-HNE in plasma, albeit
without increase of 4-HNE in tissues. LC n-3 PUFA sup-
plementation prevented this phenomenon.
We propose that the increase of oxidative stress after
HF diet consumption is linked to an alteration of anti-
oxidant defenses. In the gastro-intestinal tract, a defense
system including GPx2, is able to detoxify lipid
peroxidation products and protect against inflammation
[30,56,57]. Our results show a significant increase of
GPx2 mRNA in the duodenum of mice fed HF vs HF-
Awada et al. Nutrition & Metabolism 2013, 10:23 Page 12 of 14
http://www.nutritionandmetabolism.com/content/10/1/23ω3PL diets. Interestingly, a significant difference of
GPx2 mRNA in the jejunum was also observed between
HF vs HF-ω3PL mice. Meanwhile, we observed a signifi-
cant difference between HF vs HF-ω3TG groups in the
jejunum. This suggests that (i) the HF diet-induced-in-
flammation could alter the anti-oxidant defense system
in the intestine and (ii) the supplementation of HF diet
with LC n-3 PUFA in the form of PL is more bioactive
in the upper intestine than those in the form of TG.
Regarding the concentration of α-tocopherol, a lipid-
soluble antioxidant vitamin, we show that it was signifi-
cantly increased in the WAT of HF-ω3PL and HF-ω3TG
groups as compared to HF mice. Interestingly, tocoph-
erol level in WAT was significantly greater in HF-ω3PL
than in HF-ω3TG mice. Of note, in this study we took
care to adjust dietary tocopherol to obtain similar
concentrations in our diets. Thus, our results can be
attributed to the direct effects of PL-bound vs TG-
bound LC n-3 PUFA. Consistently, Choi et al. recently
reported that high-fat diet enhanced the oxidative stress
through the decreased level of tocopherols in the livers
of rats [58]. Thus, our findings suggest that dietary sup-
plementation with LC n-3 PUFA is beneficial for de-
creasing lipid peroxidation in high fat-fed mice, and that
the PL carrier may induce a superior bioavailability to
tocopherols or lower need for their use to counteract
oxidative stress. The enhanced level of α- tocopherol
following LC n-3 PUFA in the form of PL can also be an
effective defense against oxidative stress and inflamma-
tion. Further studies should analyze the amount and dis-
tribution of vitamin E among different tissues after the
diets. The effect of dietary n-3 PUFA in the form of PL
and TG on the activity of anti-oxidant systems should
also be clarified by further studies in humans.
Altogether, HF diet induced concomitant increase in
plasma 4-HNE, GPx-2 activation in the small intestine
and lower tocopherol level in WAT; all of these markers
being reversed by the supplementation with LC n-3
PUFA.
Conclusion
In conclusion, our study demonstrates in mice that
long-term ingestion of n-3 PUFA prevents HF diet-
induced inflammation and oxidative stress. Compared
with triacylglycerols, LC n-3 PUFA supplemented in the
form of PL exhibit superior beneficial metabolic effects
by decreasing adiposity, reducing adipocyte size and
stimulating the anti-oxidant system. Our findings should
be strengthened by dietary intervention studies in
human aimed at testing the impact of different LC n-3
PUFA molecular forms on the structure and metabolism
of adipose tissue. Such findings could support the devel-
opment of functional foods containing LC n-3 PUFA in
the form of PL participating to the prevention of thedevelopment of chronic metabolic diseases in humans
like obesity.
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